Which anticoagulant is safest for frail elderly patients with nonvalvular A-fib?
No Thumbnail Available
Meeting name
Sponsors
Date
Journal Title
Format
Article
Subject
Abstract
Consider apixaban, which demonstrated a lower adverse event (AE) rate than warfarin regardless of frailty status, for anticoagulation treatment of older patients with nonvalvular atrial fibrillation (AF); by comparison, AE rates for dabigatran and rivaroxaban were lower vs warfarin only among nonfrail individuals.
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.